Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GA Generic Assays is a German biotechnology company specializing in the development and commercialization of innovative in vitro diagnostic (IVD) solutions. Founded in 2002 and headquartered in Dahlewitz, the company focuses on the detection of autoantibodies for the diagnosis of autoimmune and infectious diseases. Their product portfolio includes ELISA, line immunoassays, and the proprietary CytoBead technology, which integrates cell-based immunofluorescence with bead-based assays. GA Generic Assays serves a global market, providing diagnostic tools for therapeutic areas such as gastroenterology, neurology, and rheumatology. The company is recognized for its expertise in identifying novel biomarkers and translating them into standardized diagnostic tests.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GA Generic Assays.